Lung Cancer Trial, By Invitation NCT06846736 Sponsor: Sheba Medical Center Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, By Invitation

NCT06846736
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are 18 years of age or older.
  • People who have been diagnosed with a cancer-related condition.
  • People whose lung cancer (a specific type called non-small cell lung cancer) has spread or is advanced, tests positive for a gene change called ALK, and who have already been treated with one of the newer ALK-blocking medicines as their first ALK treatment — these medicines include alectinib, lorlatinib, brigatinib, or ceritinib.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People for whom there is no available information about the most recent cancer treatment they received.
  • People who have not given general or specific consent to take part in this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
13 August 2023
Est. completion
1 December 2027

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

A classifier predicting outcome for advanced NSCLC ALK+ patients on ALK inhibitor treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov